GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
GeoVax Labs, Inc. (Nasdaq: GOVX) has appointed Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Prof. Lambe, a renowned vaccinology and immunology expert from the Oxford Vaccine Group, was a key figure in developing the Oxford/AstraZeneca COVID-19 vaccine. Her research focuses on designing vaccination strategies based on post-infection immune responses. GeoVax's Chief Scientific Officer, Dr. Mark Newman, highlighted how Prof. Lambe's expertise aligns with their vaccine and immunotherapy programs, including the recent BARDA Project NextGen Award for next-generation COVID-19 vaccines. David Dodd, GeoVax's Chairman and CEO, emphasized the importance of Prof. Lambe's insights for advancing their clinical trials and bringing new therapies to market.
GeoVax Labs, Inc. (Nasdaq: GOVX) ha nominato Teresa Lambe, PhD, OBE, FMedSci nel suo Comitato Consultivo Scientifico. La Prof.ssa Lambe, esperta rinomata in vaccinologia e immunologia del Oxford Vaccine Group, è stata una figura chiave nello sviluppo del vaccino COVID-19 di Oxford/AstraZeneca. La sua ricerca si concentra sulla progettazione di strategie vaccinali basate sulle risposte immunitarie post-infezione. Il Direttore Scientifico di GeoVax, Dr. Mark Newman, ha sottolineato come l'esperienza della Prof.ssa Lambe si allinei con i loro programmi di vaccini e immunoterapia, incluso il recente Premio BARDA Project NextGen per i vaccini COVID-19 di nuova generazione. David Dodd, Presidente e CEO di GeoVax, ha evidenziato l'importanza delle intuizioni della Prof.ssa Lambe per far progredire i loro studi clinici e portare nuove terapie sul mercato.
GeoVax Labs, Inc. (Nasdaq: GOVX) ha nombrado a Teresa Lambe, PhD, OBE, FMedSci en su Comité Asesor Científico. La Prof. Lambe, una experta reconocida en vacunología e inmunología del Oxford Vaccine Group, fue una figura clave en el desarrollo de la vacuna COVID-19 de Oxford/AstraZeneca. Su investigación se centra en el diseño de estrategias de vacunación basadas en las respuestas inmunitarias posteriores a la infección. El Director Científico de GeoVax, Dr. Mark Newman, destacó cómo la experiencia de la Prof. Lambe se alinea con sus programas de vacunas e inmunoterapia, incluido el reciente Premio BARDA Project NextGen para las vacunas COVID-19 de nueva generación. David Dodd, Presidente y CEO de GeoVax, enfatizó la importancia de las ideas de la Prof. Lambe para avance de sus ensayos clínicos y la introducción de nuevas terapias en el mercado.
GeoVax Labs, Inc. (Nasdaq: GOVX)는 Teresa Lambe, PhD, OBE, FMedSci를 과학 자문 위원회에 임명했습니다. Lambe 교수는 옥스포드 백신 그룹의 유명한 백신학 및 면역학 전문가로, 옥스포드/AstraZeneca COVID-19 백신 개발의 핵심 인물입니다. 그녀의 연구는 감염 후 면역 반응에 기반한 백신 전략 설계에 중점을 두고 있습니다. GeoVax의 최고 과학 책임자 Dr. Mark Newman은 Lambe 교수의 전문성이 그들의 백신 및 면역 치료 프로그램, 특히 차세대 COVID-19 백신을 위한 최근 BARDA Project NextGen 상과 어떻게 부합하는지를 강조했습니다. David Dodd, GeoVax의 회장 겸 CEO는 임상 시험을 진행하고 새로운 치료법을 시장에 도입하는 데 Lambe 교수의 통찰력이 얼마나 중요한지를 강조했습니다.
GeoVax Labs, Inc. (Nasdaq: GOVX) a nommé Teresa Lambe, PhD, OBE, FMedSci à son comité consultatif scientifique. La Professeure Lambe, experte renommée en vaccinologie et immunologie du groupe Oxford Vaccine, a été une figure clé dans le développement du vaccin COVID-19 d'Oxford/AstraZeneca. Ses recherches portent sur la conception de stratégies de vaccination basées sur les réponses immunitaires post-infection. Le Directeur scientifique de GeoVax, Dr. Mark Newman, a souligné comment l'expertise de la Professeure Lambe est en adéquation avec leurs programmes de vaccins et d'immunothérapie, y compris le récent prix BARDA Project NextGen pour les vaccins COVID-19 de nouvelle génération. David Dodd, Président et CEO de GeoVax, a souligné l'importance des idées de la Professeure Lambe pour faire avancer leurs essais cliniques et introduire de nouvelles thérapies sur le marché.
GeoVax Labs, Inc. (Nasdaq: GOVX) hat Teresa Lambe, PhD, OBE, FMedSci in seinen wissenschaftlichen Beirat berufen. Prof. Lambe, eine renommierte Expertin für Vakzinologie und Immunologie von der Oxford Vaccine Group, war eine Schlüsselperson bei der Entwicklung des COVID-19 Impfstoffs von Oxford/AstraZeneca. Ihre Forschung konzentriert sich auf die Entwicklung von Impfstrategien basierend auf den Immunantworten nach einer Infektion. Der Chief Scientific Officer von GeoVax, Dr. Mark Newman, hob hervor, wie Prof. Lambes Fachwissen mit ihren Impf- und Immuntherapieprogrammen übereinstimmt, einschließlich des jüngsten BARDA Project NextGen Awards für Impfstoffe der nächsten Generation gegen COVID-19. David Dodd, Vorsitzender und CEO von GeoVax, betonte die Bedeutung von Prof. Lambes Erkenntnissen für die Weiterentwicklung ihrer klinischen Studien und die Markteinführung neuer Therapien.
- Appointment of a highly acclaimed expert in vaccine development to the Scientific Advisory Board
- Potential acceleration of GeoVax's vaccine and immunotherapy programs
- Alignment with recent BARDA Project NextGen Award for next-generation COVID-19 vaccines
- Enhanced expertise in developing vaccines for outbreak pathogens
- None.
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development
ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board.
Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vaccine in January 2020, led the preclinical studies, and oversaw the delivery of the immune results needed to support regulatory approval in late 2020. Professor Lambe was appointed as an honorary Officer of the Order of the British Empire (OBE) for her services to Sciences and Public Health in the 2021 Queen’s Birthday Honours and received the Presidential Distinguished Service Award for the Irish Abroad in 2022. In May 2024 she was elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Professor Lambe’s research focuses on delineating the protective immune response post infection and using these findings to rationally design vaccination strategies to prevent disease. Her group is currently developing and testing vaccines against a number of outbreak pathogens including Crimean-Congo hemorrhagic fever, Ebola virus, Marburg virus and Coronaviruses. A number of these vaccines have progressed to clinical trial assessment, including vaccines against Ebola and Marburg virus.
Dr. Mark Newman, GeoVax’s Chief Scientific Officer, commented, “We are thrilled to welcome Professor Lambe to our Scientific Advisory Board. Her extensive experience and groundbreaking work in vaccine development, particularly her pivotal role in the development of the Oxford/AstraZeneca COVID-19 vaccine, will be invaluable as we continue to advance our own vaccine and immunotherapy programs. Her expertise dovetails perfectly with our product portfolio, including the recent BARDA Project NextGen Award for the development of next-generation COVID-19 vaccines. Her insights will be crucial in accelerating our efforts to bring innovative solutions to high-risk and immunocompromised populations.”
David Dodd, GeoVax’s Chairman and CEO, added, “Professor Lambe’s expertise in immunology and her innovative approach to vaccine development align perfectly with GeoVax’s mission to address some of the world’s most challenging infectious diseases. Her insights and guidance will be critical as we move forward with our clinical trials and seek to bring new, life-saving therapies to market.”
Professor Lambe expressed her enthusiasm about joining GeoVax, stating, “I am honored to join the Scientific Advisory Board of GeoVax. The Company’s dedication to developing innovative vaccines and immunotherapies is truly inspiring. I look forward to working with the team and contributing to the advancement of their promising pipeline of candidates.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
Who is Teresa Lambe and why is her appointment significant for GeoVax (GOVX)?
How might Teresa Lambe's expertise impact GeoVax's (GOVX) vaccine development programs?
What is the BARDA Project NextGen Award mentioned in relation to GeoVax (GOVX)?
What are some of the infectious diseases that GeoVax (GOVX) is targeting with its vaccine development?
